S Fulda

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. ncbi Inhibitor of apoptosis proteins as targets for anticancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24 89075, Ulm, Germany
    Expert Rev Anticancer Ther 7:1255-64. 2007
  2. ncbi Cell death in hematological tumors
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Apoptosis 14:409-23. 2009
  3. ncbi Caspase-8 in cancer biology and therapy
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Cancer Lett 281:128-33. 2009
  4. ncbi Betulinic acid: a natural product with anticancer activity
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Mol Nutr Food Res 53:140-6. 2009
  5. ncbi Targeting apoptosis resistance in rhabdomyosarcoma
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Curr Cancer Drug Targets 8:536-44. 2008
  6. ncbi Tumor resistance to apoptosis
    Simone Fulda
    Children s Hospital, Ulm University, Ulm 89075, Germany
    Int J Cancer 124:511-5. 2009
  7. ncbi 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8
    S Fulda
    Department of Hematology Oncology, University Children s Hospital, Ulm, Germany
    Oncogene 25:5125-33. 2006
  8. ncbi Modulation of apoptosis signaling for cancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24, D 89075, Ulm, Germany
    Arch Immunol Ther Exp (Warsz) 54:173-5. 2006
  9. ncbi Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo
    Hubert Kasperczyk
    University Children s Hospital, Eythstr 24, D 89075 Ulm, Germany
    FASEB J 23:21-33. 2009
  10. ncbi Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Anticancer Agents Med Chem 8:533-9. 2008

Collaborators

Detail Information

Publications85

  1. ncbi Inhibitor of apoptosis proteins as targets for anticancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24 89075, Ulm, Germany
    Expert Rev Anticancer Ther 7:1255-64. 2007
    ..Thus, inhibition of IAPs such as X chromosome-linked IAP may prove to be a successful strategy to overcome apoptosis resistance of human cancers that deserves further exploitation...
  2. ncbi Cell death in hematological tumors
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Apoptosis 14:409-23. 2009
    ....
  3. ncbi Caspase-8 in cancer biology and therapy
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Cancer Lett 281:128-33. 2009
    ..Therefore, caspase-8 presents a promising target to restore defective apoptosis programs in cancers in order to overcome resistance...
  4. ncbi Betulinic acid: a natural product with anticancer activity
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Mol Nutr Food Res 53:140-6. 2009
    ..Thus, mitochondrion-targeted agents such as BA hold great promise as a novel approach to bypass certain forms of drug resistance in human cancers...
  5. ncbi Targeting apoptosis resistance in rhabdomyosarcoma
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Curr Cancer Drug Targets 8:536-44. 2008
    ..Thus, molecular targeted therapies that are specifically directed to the defects in apoptosis programs, open novel perspectives to restore apoptosis sensitivity in rhabdomyosarcoma...
  6. ncbi Tumor resistance to apoptosis
    Simone Fulda
    Children s Hospital, Ulm University, Ulm 89075, Germany
    Int J Cancer 124:511-5. 2009
    ..Hence, a better understanding of the molecular mechanisms underlying tumor resistance to apoptotic cell death is expected to provide the basis for a rational approach to develop molecular targeted therapies...
  7. ncbi 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8
    S Fulda
    Department of Hematology Oncology, University Children s Hospital, Ulm, Germany
    Oncogene 25:5125-33. 2006
    ....
  8. ncbi Modulation of apoptosis signaling for cancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24, D 89075, Ulm, Germany
    Arch Immunol Ther Exp (Warsz) 54:173-5. 2006
    ..Therefore, insights into the mechanisms regulating drug-induced apoptosis provide rational targets for novel therapeutic interventions...
  9. ncbi Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo
    Hubert Kasperczyk
    University Children s Hospital, Eythstr 24, D 89075 Ulm, Germany
    FASEB J 23:21-33. 2009
    ....
  10. ncbi Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Anticancer Agents Med Chem 8:533-9. 2008
    ..Thus, targeting IAPs, e.g. by antisense approaches or small molecule inhibitors, presents a promising novel approach for future drug development and may proof to be a successful strategy to overcome apoptosis resistance of human cancers...
  11. ncbi Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Cancer Detect Prev 30:217-23. 2006
    ..DISCUSSION: Further insights into the signaling network and interaction points modulated by resveratrol may provide the basis for novel drug discovery programs to exploit resveratrol for the prevention and treatment of human diseases...
  12. ncbi Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
    S Fulda
    University Children s Hospital, Ulm, Germany
    Oncogene 25:4798-811. 2006
    ....
  13. ncbi Modulation of TRAIL-induced apoptosis by HDAC inhibitors
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Curr Cancer Drug Targets 8:132-40. 2008
    ....
  14. ncbi Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Cancer Res 66:10016-23. 2006
    ..Thus, our study provides novel insight into the biology of this tumor, which may have important clinical implications...
  15. ncbi HIF-1-regulated glucose metabolism: a key to apoptosis resistance?
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Cell Cycle 6:790-2. 2007
    ..Thus, Hif-1alpha and hypoxia-inducible genes represent attractive targets for the development of pharmacological inhibitors, which may offer new therapeutic options for a wide range of adult and also pediatric malignancies...
  16. ncbi Exploiting apoptosis pathways for the treatment of pediatric cancers
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Pediatr Blood Cancer 53:533-6. 2009
    ..This approach is expected to open new and more effective approaches for the treatment of childhood cancers...
  17. ncbi Apoptosis pathways and neuroblastoma therapy
    S Fulda
    University Children s Hospital, Ulm, Germany
    Curr Pharm Des 15:430-5. 2009
    ..Therefore, a better understanding of the signaling pathways and molecules that govern apoptosis in neuroblastoma cells is expected to open new avenues for the design of molecular targeted therapies for neuroblastoma...
  18. ncbi Inhibitor of apoptosis proteins in hematological malignancies
    S Fulda
    University Children s Hospital, Ulm University, Ulm, Germany
    Leukemia 23:467-76. 2009
    ..Thus, IAPs present promising targets for the development of new biomarkers and cancer therapeutics in hematological malignancies...
  19. ncbi Modulation of apoptosis by natural products for cancer therapy
    Simone Fulda
    Children s Hospital, Ulm University, Ulm, Germany
    Planta Med 76:1075-9. 2010
    ..This review presents some examples of how apoptosis pathways are targeted by selected naturally occurring agents and how these events can be exploited for cancer therapy...
  20. ncbi Targeting mitochondria for cancer therapy
    Simone Fulda
    University Children s Hospital, Ulm University, Eythstrasse 24, D 89075 Ulm, Germany
    Nat Rev Drug Discov 9:447-64. 2010
    ....
  21. ncbi The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma
    S Fulda
    University Children s Hospital, Ulm, Germany
    Curr Cancer Drug Targets 9:729-37. 2009
    ..Eventually, PI3K/Akt/mTOR targeting agents may open novel perspectives to improve the poor prognosis of patients with neuroblastoma especially in advanced stages of the disease...
  22. ncbi Inhibitor of apoptosis (IAP) proteins: novel insights into the cancer-relevant targets for cell death induction
    Simone Fulda
    University Children s Hospital, Eythstrasse 24, Ulm, Germany
    ACS Chem Biol 4:499-501. 2009
    ..Structure-based development of selective IAP inhibitors now provides, for the first time, evidence that simultaneous inhibition of the c-IAP proteins and XIAP is necessary for efficient induction of cancer cell death by IAP antagonists...
  23. ncbi Apoptosis signaling in cancer stem cells
    Simone Fulda
    University Children s Hospital, Eythstr 24, D 89075 Ulm, Germany
    Int J Biochem Cell Biol 42:31-8. 2010
    ..Here we provide a brief review of the literature vis a vis the various mechanisms of defective apoptotic signaling in CSCs with potential for therapeutic intervention...
  24. ncbi Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
    Simone Fulda
    University Children s Hospital, Eythstr, Ulm, Germany
    J Cell Mol Med 13:1221-7. 2009
    ..How apoptosis pathways can be exploited for the treatment of pancreatic cancer will be discussed in this review...
  25. ncbi Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Br J Haematol 145:441-54. 2009
    ....
  26. ncbi Betulinic Acid for cancer treatment and prevention
    Simone Fulda
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany Tel 49 731 500 57034 E mail
    Int J Mol Sci 9:1096-107. 2008
    ..Thus, mitochondrion-targeted agents such as betulinic acid hold great promise as a novel therapeutic strategy in the treatment of human cancers...
  27. ncbi Targeting mitochondrial apoptosis by betulinic acid in human cancers
    Simone Fulda
    University Children s Hospital, Eythstr 24, D 89075 Ulm, Germany
    Drug Discov Today 14:885-90. 2009
    ..Thus, mitochondrion-targeted agents such as BA hold great promise as a novel approach to overcome certain forms of drug resistance in human cancers...
  28. ncbi Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy
    K Stahnke
    Department of Pediatrics, University Children's Hospital, Ulm, Germany
    Blood 98:3066-73. 2001
    ....
  29. ncbi Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8
    S Hacker
    University Children s Hospital, Ulm, D 89075, Germany
    Oncogene 28:3097-110. 2009
    ....
  30. ncbi PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis
    A Bender
    Department of Hematology Oncology, University Children s Hospital, Ulm, Germany
    Oncogene 30:494-503. 2011
    ..Thus, targeting PI3K presents a novel and promising strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis, which has important implications for the development of targeted therapies for neuroblastoma...
  31. ncbi The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
    M A Westhoff
    University Children s Hospital, Ulm, Germany
    Oncogene 28:3586-96. 2009
    ....
  32. ncbi Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity
    Meike Vogler
    University Children s Hospital, Prittwitzstr 43, 89075 Ulm, Germany
    Oncogene 24:7190-202. 2005
    ..Thus, Smac agonists may be useful in cancer therapy, for example, for tumor control in minimal residual disease. Oncogene (2005) 24, 7190-7202. doi:10.1038/sj.onc.1208876; published online 8 August 2005...
  33. ncbi Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition
    S Giagkousiklidis
    University Children s Hospital, Ulm, Germany
    Oncogene 26:7006-16. 2007
    ..In conclusion, targeting XIAP, for example by small molecules, is a promising novel approach to enhance radiosensitivity of pancreatic cancer that warrants further investigation...
  34. ncbi Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation
    S Hacker
    University Children s Hospital, Ulm, Germany
    Oncogene 30:2275-81. 2011
    ..These findings have important clinical implications for the design of experimental treatment protocols for medulloblastoma...
  35. ncbi Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase
    Stavros Giagkousiklidis
    University Children's Hospital, Ulm, Germany
    Cancer Res 65:10502-13. 2005
    ..In conclusion, our findings provide evidence that targeting IAPs (e.g., by Smac agonists) is a promising strategy to enhance radiosensitivity in human cancers...
  36. ncbi 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG
    G Strauss
    University Children s Hospital, Ulm, Germany
    Cell Death Differ 15:332-43. 2008
    ..These results strongly indicate that oxidative damage-induced nuclear translocation of AIF and EndoG in 4-OOH-CY-treated T cells might represent an alternative death pathway in the absence of caspase activity...
  37. ncbi Sensitization for anticancer drug-induced apoptosis by betulinic Acid
    Simone Fulda
    University Children s Hospital, Prittwitzstrasse 43, Ulm 89075, Germany
    Neoplasia 7:162-70. 2005
    ..These findings indicate that using BetA as sensitizer in chemotherapy-based combination regimens may be a novel strategy to enhance the efficacy of anticancer therapy, which warrants further investigation...
  38. ncbi Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation
    N Azoitei
    Department of Internal Medicine I, University of Ulm, and Children s Hospital, Ulm, Germany
    Oncogene 26:6536-45. 2007
    ..TNK1 therefore acts as a novel molecular switch that can determine the properties of TNFalpha signaling and therefore cell death...
  39. ncbi Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells
    M A Westhoff
    Department of Hematology Oncology, University Children s Hospital, Ulm, Germany
    Oncogene 27:5169-81. 2008
    ....
  40. ncbi TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB
    Harald Ehrhardt
    Dr von Haunersches Kinderspital, Department of Hematology Oncology, Lindwurmstr 4, Munich 80337, Germany
    Oncogene 22:3842-52. 2003
    ..Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors...
  41. ncbi Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
    Melanie Fakler
    University Children s Hospital, Ulm, Germany
    Blood 113:1710-22. 2009
    ..Thus, XIAP inhibitors present a promising novel approach for apoptosis-based therapy of childhood ALL...
  42. ncbi Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance
    M Kilic
    University Children s Hospital, Ulm, Germany
    Oncogene 26:2027-38. 2007
    ..Thus, hypoxia-inducible genes may represent novel targets for therapeutic intervention in some pediatric tumors, which warrants further investigation...
  43. ncbi NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition
    K La Ferla-Brühl
    University Children s Hospital, Ulm, Germany
    Oncogene 26:571-82. 2007
    ..Instead, proteasome inhibitors, which enhanced TRAIL-induced apoptosis in an NF-kappaB-independent manner, may open new perspectives to increase the efficacy of TRAIL-based regimens in glioblastoma, which warrants further investigation...
  44. ncbi Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling
    Simone Fulda
    University Childrens Hospital, Prittwitzstrasse 43, 89075 Ulm, Germany
    Eur J Cancer 41:786-98. 2005
    ..Thus, resveratrol is a potent sensitiser for TRAIL in certain tumours. However, it may be ineffective in others, e.g. in tumours with enhanced Bcl-2 expression or defective death receptor signalling...
  45. ncbi Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response
    Sabine Karl
    University Children s Hospital, Ulm, Germany
    J Cell Mol Med 13:4239-56. 2009
    ..By demonstrating that NF-kappaB promotes DNA damage formation and apoptosis upon pulse treatment with DNA intercalators, our findings provide novel insights into the control of the DNA damage response by NF-kappaB in glioblastoma...
  46. ncbi Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol
    Simone Fulda
    University Children's Hospital, Ulm, Germany
    Cancer Res 64:337-46. 2004
    ..Thus, this combined sensitizer (resveratrol)/inducer (e.g., TRAIL) strategy may be a novel approach to enhance the efficacy of TRAIL-based therapies in a variety of human cancers...
  47. ncbi Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells
    Simone Fulda
    University Children s Hospital, Prittwitzstr 43, D 89075 Ulm, Germany
    Oncogene 23:7611-20. 2004
    ..Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation...
  48. ncbi Apoptosis signaling in tumor therapy
    Simone Fulda
    University Children s Hospital, Prittwitzstr 43, D 89075 Ulm, Germany
    Ann N Y Acad Sci 1028:150-6. 2004
    ..Further insights into the mechanisms regulating apoptosis in response to anticancer therapy and how cancer cells evade cell death may provide novel opportunities for drug development...
  49. ncbi Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses
    D Fabricius
    Department of Pediatrics, University of Ulm, Ulm, Germany
    Leukemia 25:1111-21. 2011
    ..Our results may stimulate the development of novel adoptive T cell transfer approaches for the management of BCP-ALL...
  50. ncbi Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma
    Meike Vogler
    University Children s Hospital, Ulm University, Ulm, Germany
    Cancer Res 69:2425-34. 2009
    ..These findings build the rationale for further (pre)clinical development of XIAP inhibitors and TRAIL against pancreatic cancer...
  51. ncbi Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
    Simone Fulda
    University Children s Hospital, Ulm, Germany
    Nat Med 8:808-15. 2002
    ..Thus, Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies...
  52. ncbi CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling
    Gudrun Strauss
    University Children s Hospital Ulm, 89075 Ulm, Germany
    J Exp Med 206:1379-93. 2009
    ....
  53. ncbi Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin
    Selim Corbacioglu
    Department of Pediatrics, University of Ulm, Eythstr 24, D 89075 Ulm, Germany
    Blood 108:3504-13. 2006
    ..The findings presented may have immediate therapeutic impact for a subgroup of childhood AML-expressing c-KIT mutations...
  54. ncbi Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner
    Susanne Andrea Gatz
    Children s Hospital of the University of Ulm, Eythstrasse 24, D 89075 Ulm, Germany
    Carcinogenesis 29:519-27. 2008
    ..Repression of error-prone recombination subpathways could at least partially explain the chemopreventive effects of this natural plant constituent in animal cancer models...
  55. ncbi Activation of Akt predicts poor outcome in neuroblastoma
    Daniela Opel
    University Children s Hospital, Ulm, Germany
    Cancer Res 67:735-45. 2007
    ....
  56. ncbi Exploiting death receptor signaling pathways for tumor therapy
    Simone Fulda
    University Children s Hospital, Prittwitzstr 43, 89075 Ulm, Germany
    Biochim Biophys Acta 1705:27-41. 2004
    ..Thus, agents designed to selectively activate death receptor pathways may enhance the efficacy of conventional therapies and may even overcome some forms of cancer resistance...
  57. ncbi Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis
    Isabelle Mader
    University Children s Hospital, Ulm, Germany
    FASEB J 24:1997-2009. 2010
    ..The discovery of this novel activity of resveratrol significantly advances the knowledge of fat tissue regulation by resveratrol and has important implications for its use in metabolic and age-related diseases...
  58. ncbi Adhesion-mediated apoptosis resistance in cancer
    Mike Andrew Westhoff
    University Children s Hospital, Eythstr 24, 89075 Ulm, Germany
    Drug Resist Updat 12:127-36. 2009
    ..Thus, the tools to overcome AMAR are already at our disposal and using them in this novel context of AMAR should lead to significant therapeutic benefit...
  59. ncbi HDAC inhibitors: double edge sword for TRAIL cancer therapy?
    Simone Fulda
    University Children's Hospital, Ulm, Germany
    Cancer Biol Ther 4:1113-5. 2005
  60. ncbi Apoptosis in hematological disorders
    Klaus Michael Debatin
    University Children s Hospital, Prittwitzstr 43, 89075 Ulm, Germany
    Semin Cancer Biol 13:149-58. 2003
    ..Understanding the molecular events by which tumor cells evade apoptotic deletion and which induce apoptosis by cytotoxic therapies, have provided a paradigm to link normal growth control, malignant transformation and response to therapy...
  61. ncbi Identification of a novel pro-apoptotic role of NF-?B in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells
    C Jennewein
    University Children s Hospital, Ulm, Germany
    Oncogene 31:1468-74. 2012
    ..Thus, this study demonstrates for the first time that NF-?B exerts a pro-apoptotic role in TRAIL- and CD95-induced apoptosis in glioblastoma cells by facilitating DISC formation...
  62. ncbi Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells
    M Vogler
    University Children s Hospital, Ulm, Germany
    Oncogene 26:248-57. 2007
    ..Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications...
  63. ncbi Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis
    Sandra Loeder
    University Children s Hospital, University of Ulm, Ulm, Germany
    Int J Cancer 126:2216-28. 2010
    ..Thus, small molecule XIAP inhibitors present a promising novel approach to enhance CD95-induced apoptosis in childhood acute leukemia...
  64. ncbi TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells
    Christian Beltinger
    University Children s Hospital, Ulm 89075, Germany
    Cancer Gene Ther 9:372-81. 2002
    ..Because combined treatment also augmented the bystander cell kill, the addition of TRAIL may increase the efficacy of TK/GCV gene therapy of neuroblastoma...
  65. ncbi Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner
    Pamela Fischer-Posovszky
    Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany
    Am J Clin Nutr 92:5-15. 2010
    ..This effect of caloric restriction can be mimicked by resveratrol, a natural plant product present in grapes and red wine, which is known as a potent activator of sirtuin 1 [silent mating type information regulation 2 homolog 1 (Sirt1)]...
  66. ncbi Targeting apoptosis pathways in cancer therapy
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, 89075 Ulm, Germany
    Curr Cancer Drug Targets 4:569-76. 2004
    ..Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development...
  67. ncbi Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis
    Daniela Opel
    University Children s Hospital, Ulm, Germany
    Cancer Res 68:6271-80. 2008
    ..By showing that PI3K inhibition broadly primes glioblastoma cells for apoptosis, our findings provide the rationale for using PI3K inhibitors in combination regimens to enhance TRAIL- or chemotherapy-induced apoptosis in glioblastoma...
  68. ncbi Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition
    Johannes U Ammann
    University Children s Hospital, Ulm, Germany
    Int J Cancer 124:1301-11. 2009
    ..Thus, NF-kappaB inhibitors may open new perspectives to potentiate the efficacy of TRAIL-based protocols in the treatment of neuroblastoma...
  69. ncbi RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis
    S Löder
    University Children s Hospital, Ulm, Germany
    Leukemia 26:1020-9. 2012
    ..These data have important implications for developing apoptosis-targeted therapies in childhood leukemia...
  70. ncbi Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups
    S C Lück
    Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
    Leukemia 25:1728-38. 2011
    ....
  71. ncbi A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia
    Sandra Loeder
    University Children s Hospital, Ulm, Germany
    Cancer Res 69:8977-86. 2009
    ....
  72. ncbi Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma
    Sri Hari Krishna Vellanki
    University Children s Hospital, Ulm University, D 89075 Ulm, Germany
    Neoplasia 11:743-52. 2009
    ....
  73. ncbi Death receptor signaling in cancer therapy
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, 89075 Ulm, Germany
    Curr Med Chem Anticancer Agents 3:253-62. 2003
    ..Thus, novel strategies targeting tumor cell resistance will be based on insights into the molecular mechanisms of cell death...
  74. ncbi Signaling through death receptors in cancer therapy
    Simone Fulda
    University Children s Hospital, Prittwitzstr 43, 89075 Ulm, Germany
    Curr Opin Pharmacol 4:327-32. 2004
    ..Thus, insights into the mechanisms regulating apoptosis in response to anticancer therapy and the ways in which cancer cells evade apoptosis might provide new opportunities for drug development...
  75. ncbi Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy
    Hubert Kasperczyk
    Department of Hematology, Oncology, University Children's Hospital, Prittwitzstr. 43, Ulm D-89075, Germany
    Oncogene 24:6945-56. 2005
    ....
  76. ncbi DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells
    Ping Ji
    Department of Medicine, Hematology and Oncology, University of Munster, Munster, Germany
    Int J Cancer 121:706-13. 2007
    ..Taken together, these analyses demonstrate that cyclin A1 exerts antiapoptotic functions by interacting with retinoblastoma and Ku proteins in leukemia cells...
  77. ncbi Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany
    Oncogene 21:2283-94. 2002
    ..g. by Bcl-2 and by XIAP, these findings may have important clinical implication. Thus, strategies targeting the molecular basis of resistance towards TRAIL may be necessary in some tumors for cancer therapy with TRAIL...
  78. ncbi Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany
    Oncogene 23:6702-11. 2004
    ..Thus, this combined sensitizer (resveratrol)/inducer (cytotoxic drugs) concept may be a novel strategy to enhance the efficacy of anticancer therapy in a variety of human cancers...
  79. ncbi Modulation of TRAIL signaling for cancer therapy
    Simone Fulda
    University Children's Hospital, D-89075 Ulm, Germany
    Vitam Horm 67:275-90. 2004
    ..Thus, novel strategies targeting tumor cell resistance will be based on further insights into the molecular mechanisms of cell death, e.g., triggered by TRAIL...
  80. ncbi Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells
    Frans Van Valen
    Department of Orthopaedics, Laboratory for Experimental Orthopaedic Research, University Hospital, Domagkstrasse 3, 48149 Munster, Germany
    Int J Cancer 107:929-40. 2003
    ....
  81. ncbi Apoptosis pathways in neuroblastoma therapy
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany
    Cancer Lett 197:131-5. 2003
    ..Thus, novel strategies targeting resistance of neuroblastoma cells will be based on insights into the molecular mechanisms of apoptosis as well as other forms of cell death...
  82. ncbi Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression
    Carl Friedrich Classen
    University Children s Hospital Ulm, Prittwitzstrasse 43, D 89070 Ulm, Germany
    Haematologica 88:509-21. 2003
    ..Here, we clarify the mechanism underlying cross-resistance of drug-resistant variants of the T-leukemia cell line CEM towards natural killer cells...
  83. ncbi Apoptosis pathways: turned on their heads?
    Simone Fulda
    Drug Resist Updat 6:1-3. 2003
  84. ncbi IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
    Simone Fulda
    University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany
    Oncogene 21:2295-308. 2002
    ....